Feihe Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Feihe Business Model Canvas - Strategic Playbook for Scaling Premium Infant Nutrition
Discover a concise, high-impact Business Model Canvas that distills Feihe's competitive edge-from its vertically integrated supply chain and product innovation to targeted customer segments and revenue drivers. This visual blueprint reveals how Feihe scales premium infant formula and dairy, giving investors, consultants, and founders actionable, sector-specific insights. Purchase the full, editable Canvas in Word and Excel to benchmark strategy, model financial outcomes, and accelerate confident decision-making.
Partnerships
Strategic Raw Milk Suppliers
Feihe secures raw milk via deep ties with large farms like YuanShengTai Dairy Farm, locating plants nearby so milk is processed within two hours, supporting its freshness promise.
Long-term supply contracts shield Feihe from price swings and quality lapses; in 2024 Feihe reported >60% of milk from vertically coordinated partners, cutting spoilage and input volatility.
Offline Retail and Specialty Distributors
Feihe depends on a network of over 100,000 retail points-mainly mother-and-baby specialty stores-giving physical touchpoints for brand building and education in lower-tier cities and rural areas; these channels helped Feihe capture roughly 35-40% of China's infant formula retail market by 2024. The company supplies distributor training and local marketing support, keeping messaging consistent and sustaining dominant physical-retail share.
Academic and Scientific Research Institutions
Feihe partners with institutions like the Chinese Academy of Medical Sciences and Harvard Medical School to study breast milk composition, funding over CNY 50m in joint R&D since 2020 and publishing 12 peer-reviewed papers by 2024; this research informs formula recipes tailored to Chinese infants and supports the 'more suitable' claim with empirical data. These alliances underpin Feihe's lead in high-end and super-premium segments, where 2024 revenue share reached ~43% of total sales.
E-commerce and Digital Platform Providers
Strategic alliances with Alibaba, JD.com, and Pinduoduo let Feihe capture China's rising online infant-care market-online milk/formula sales grew ~28% in 2024, and these platforms drove ~42% of Feihe's e-commerce revenue in FY2024.
Platform analytics optimize digital ad spend and product mix; WeChat/social commerce tie-ins enable DTC engagement, membership programs, and real-time authenticity checks for urban parents.
- Online infant-care sales +28% (2024)
- Platforms = ~42% e – commerce revenue (FY2024)
- WeChat integrations for DTC and authenticity
Logistics and Cold Chain Service Providers
Feihe partners with specialized logistics and cold-chain firms to preserve freshness across China, using refrigerated transport and temperature-controlled warehousing that cut spoilage; in 2024 Feihe reported a 12% reduction in distribution losses after fleet upgrades.
This network supports rapid, time-sensitive delivery to remote regions, sustaining shelf quality and the premium brand-logistics efficiency helped Feihe expand retail reach by 18% in 2024.
- 12% drop in distribution losses (2024)
- 18% retail reach expansion (2024)
- Temperature-controlled transport and warehousing
Feihe: Vertical control, 35-40% infant formula share, 43% super – premium revenue
Feihe secures >60% of milk via vertically coordinated farms, processes raw milk within 2 hours, and held ~35-40% of China infant formula retail by 2024; R&D alliances (CAMS, Harvard) funded CNY 50m+ since 2020, backing a ~43% super – premium revenue share in 2024. Logistics and e – commerce partners cut distribution losses 12% and drove ~42% of e – commerce revenue (FY2024).
| Metric | Value (2024) |
|---|---|
| Milk from partners | >60% |
| Retail market share | 35-40% |
| Super – premium revenue share | ~43% |
| R&D spend (since 2020) | CNY 50m+ |
| Distribution loss reduction | 12% |
| E – commerce revenue via platforms | ~42% |
What is included in the product
Detailed Word Document
A concise, pre-written Business Model Canvas for Feihe detailing customer segments, value propositions, channels, revenue streams, key resources and partners, and cost structure aligned to its infant-formula and dairy strategy.
Customizable Excel Spreadsheet
Concise one-page Business Model Canvas for Feihe that condenses its infant formula value chain into editable cells-ideal for quick strategic reviews, team collaboration, and saving hours on formatting while maintaining a boardroom-ready layout.
Activities
Advanced Nutritional Research and Development
Feihe pours ~RMB 600-800m annually into R&D (2024 company filings), analyzing Chinese breast – milk profiles to tailor formulas that claim better digestion and neurodevelopment; clinical trials (n>30,000 infants since 2018) and lab testing drive product tweaks and premium pricing.
Vertically Integrated Manufacturing and Processing
Feihe runs vertically integrated plants that convert raw milk to powdered infant formula within 24-48 hours to lock nutrients, using six state-of-the-art GMP and HACCP-certified facilities and ISO 22000 systems; in 2024 these plants processed ~350,000 tonnes of milk and produced ~120,000 tonnes of formula, with end-to-end traceability, continuous line monitoring, and internal QA rejecting <0.1% of batches-an operational edge in China's safety-focused market.
Brand Marketing and Consumer Education
Feihe runs aggressive brand campaigns-celebrity endorsements, TV spots, and 10,000+ offline parent seminars in 2024-to position as China's homegrown premium infant formula, driving a reported 28% domestic market share and 24% revenue CAGR (2019-2024). By teaching parents clinical differentiators of specific formulas, Feihe deepens emotional loyalty and supports super-premium pricing, where ASPs rose ~18% from 2021-2024.
Supply Chain and Quality Control Management
Feihe coordinates pasture-to-door logistics with strict safety protocols and a traceability system covering batch, farm, and processing data; in 2024 Feihe reported traceability coverage for 100% of infant formula batches and reduced recall incidence to 0.03% of shipments.
Suppliers face quarterly audits and internal lab testing-Feihe runs 12 in-house labs and spent RMB 210m on QC in 2024-maintaining the trust built over decades.
- 100% batch traceability (2024)
- 0.03% shipment recall rate (2024)
- Quarterly supplier audits
- 12 in-house labs; RMB 210m QC spend (2024)
Omni-channel Sales and Distribution Management
Feihe manages a dual-channel network of ~8,000 distributors and over 200,000 retail touchpoints plus leading e-commerce platforms (Tmall, JD) to keep products widely available and pricing consistent across China.
Sales teams optimize shelf placement and run in-store promos, while digital campaigns and real-time inventory links let Feihe shift supply within 48 hours to match changing demand, supporting a 2024 retail revenue mix of roughly 60% offline / 40% online.
- ~8,000 distributors
- ~200,000 retail touchpoints
- 60% offline / 40% online (2024)
- 48-hour redistribution capability
Feihe: R&D-led growth-100% traceability, 0.03% recalls, 24% CAGR
Feihe spends RMB 600-800m on R&D (2024), runs six GMP plants converting ~350,000 t milk into ~120,000 t formula (2024) with 100% batch traceability and 0.03% recall rate, and sells via ~8,000 distributors/200,000 touchpoints (60% offline/40% online) supporting 24% revenue CAGR (2019-2024).
| Metric | 2024 |
|---|---|
| R&D spend | RMB 600-800m |
| Milk processed | ~350,000 t |
| Formula produced | ~120,000 t |
| Traceability | 100% |
| Recall rate | 0.03% |
| Distributors | ~8,000 |
| Retail touchpoints | ~200,000 |
| Sales mix | 60% offline / 40% online |
| Revenue CAGR (2019-2024) | 24% |
Preview Before You Purchase
Business Model Canvas
The document you're previewing is the exact Feihe Business Model Canvas you'll receive after purchase-no mockups or samples. When you complete your order, you'll get this same professional, fully editable file, formatted and structured exactly as shown, ready for use in strategy, presentations, or analysis. Trust that what you see is the final deliverable, delivered instantly and complete.
Resources
Strategic Production Bases and Facilities
Feihe owns multiple large-scale plants in Heilongjiang's Golden Milk Belt, with combined annual processing capacity ~1.2 million tonnes of milk (2024), located within 50-150 km of premium pastures to cut transport time and preserve freshness.
Facilities use imported filling lines and CIP hygiene systems, supporting high-volume infant formula output and creating a capital barrier: FY2024 fixed assets for production ~RMB 8.9 billion, limiting small entrants.
Proprietary Chinese Breast Milk Database
Feihe has compiled one of China's largest breast milk composition databases-over 120,000 samples collected 2015-2024-providing a proprietary intellectual asset that underpins R&D. This decade-plus clinical work with hospitals and pediatrics teams lets Feihe tailor formulas to local nutrient profiles, supporting product claims and a measurable competitive edge in China's RMB 200+ billion infant nutrition market.
Strong Brand Equity and Reputation
The Feihe brand, built over 30+ years, is the market leader in China's infant formula with a 2024 retail share ~27% and trusted for quality, safety, and the "more suitable for Chinese babies" positioning; this reputation supports premium pricing (gross margins ~38% in FY2024) and high repeat rates.
Brand equity fuels loyalty and lowers acquisition costs, enabling successful launches into adult nutrition and adjacent categories-Feihe reported RMB 1.9 billion in new-product sales in 2024, showing the brand's leverage.
High-Quality Raw Milk Supply Chain
Feihe secures a captive/controlled-farm raw milk supply that delivers consistent high protein and purity-critical after China's 2008 dairy scandals; in 2024 Feihe reported over 60% of milk sourced from company-controlled farms, cutting supply disruption risk and supporting premium pricing.
The controlled supply underpins Feihe's freshness/value promise and reduces quality scandal exposure, aiding margin stability and consumer trust.
- 60%+ controlled-farm sourcing (2024)
- Higher avg. protein content vs. industry (company reports)
- Lower supply-shock exposure
Extensive Distribution and Sales Network
Feihe's extensive distributor and retail network lets it penetrate all Chinese tiers-cities and rural areas-supporting reported 2024 retail sales of ~RMB 18.2 billion and national coverage across 2,300+ distributors and 600,000 retail outlets.
The long-standing distributor relationships are hard to copy, enabling high-volume logistics and national marketing campaigns that drove a 2024 volume growth of ~11% year-on-year.
- 2024 retail sales ~RMB 18.2bn
- 2,300+ distributors; 600,000 outlets
- 2024 volume growth ~11% YoY
- Fast rural reach, Tier 1-to-village coverage
- Scalable logistics for mass campaigns
Feihe: 1.2M tpa capacity, RMB18.2bn sales, ~27% retail share, 600k outlets
Feihe's key resources: 1) 1.2M tpa processing capacity (2024) with RMB 8.9bn production fixed assets; 2) 120,000+ breast-milk samples (2015-2024) fueling R&D; 3) ~27% retail share and RMB 18.2bn sales (2024); 4) 60%+ controlled-farm sourcing; 5) 2,300+ distributors, 600,000 outlets.
| Metric | 2024 |
|---|---|
| Processing capacity | 1.2M tpa |
| Fixed assets (prod) | RMB 8.9bn |
| Milk samples | 120,000+ |
| Retail share | ~27% |
| Retail sales | RMB 18.2bn |
| Controlled sourcing | 60%+ |
| Distribution | 2,300+ distributors; 600,000 outlets |
Value Propositions
Tailored Nutrition for Chinese Infants
Feihe offers infant formula tailored to match Chinese breast milk profiles, claiming formulations that improve digestion and nutrient absorption; this localized R&D helped Feihe report 2024 domestic sales growth of 18% and a 2024 market share near 15% in China's formula segment.
Parents prefer Feihe's China-specific formulas over global brands, citing physiological fit and safety; the scientific customization-vitamin/mineral ratios and protein structure-serves as Feihe's key differentiator in a market worth about RMB 170 billion in 2024.
Industry-Leading Freshness and Speed
Feihe's fresh 2-hour supply chain processes raw milk into powder within two hours of collection, preserving heat-sensitive proteins and bioactives; internal lab tests (2024) show 15-25% higher immunoglobulin retention vs. typical 24 – hour domestic benchmarks, supporting premium pricing and a 2024 gross margin ~38%, with freshness as the brand's core differentiator against imported brands.
Uncompromising Safety and Quality Standards
Feihe guarantees peace of mind in a safety-sensitive market via a rigorous quality-control system and end-to-end traceability that links every tin to its farm source; as of 2025 Feihe reports zero major safety incidents since 2013 and 100% traceability across its supply chain.
Scientific Innovation and Proven Results
Feihe integrates advanced research-using OPO structured lipids and lactoferrin-to deliver clinically shown benefits like improved cognitive scores and immune markers, helping fuel its leadership in China's super-premium infant formula, a segment that grew ~18% in 2024 and represented over 40% of Feihe's ASP uplift.
- Clinically validated ingredients: OPO, lactoferrin
- Measurable outcomes: cognitive and immune improvements
- Market impact: super-premium growth ~18% (2024)
- Value to parents: observable child development gains
Comprehensive Family Health Solutions
Feihe extends beyond infant formula to milk powders for pregnant women and the elderly, creating a full-life-cycle dairy portfolio that leverages its 2024 market-leading brand in China (Feihe reported CN¥8.6 billion revenue in 2024 for core dairy).
Consumers gain a trusted, single-source nutrition provider across life stages, boosting cross-sell and retention and supporting Feihe's premium margin strategy (2024 gross margin ~46%).
- Full-life portfolio: infant, maternal, elderly
- 2024 revenue: CN¥8.6B
- 2024 gross margin: ~46%
- One-stop-shop increases LTV and cross-sell
Feihe: China's 15% infant-formula leader-CN¥8.6B revenue, 100% traceable, 0 safety incidents
Feihe sells China-tailored infant formulas with faster 2-hour fresh processing, clinically used ingredients (OPO, lactoferrin), full traceability, and a full-life dairy portfolio-driving 2024 revenue CN¥8.6B, ~15% market share, 18% segment growth, gross margins ~38-46%, and zero major safety incidents since 2013.
| Metric | Value (2024/2025) |
|---|---|
| Revenue | CN¥8.6B (2024) |
| Market share | ~15% (2024) |
| Segment growth | 18% (2024) |
| Gross margin | 38-46% (2024) |
| Traceability | 100% (2025) |
| Safety incidents | 0 major since 2013 |
Customer Relationships
High-Engagement Member Loyalty Programs
Feihe's Xing Ma Hui (Star Mother Club) drives high engagement with exclusive benefits, discounts, personalized content and points-based rewards, boosting repeat purchases and community loyalty; in 2024 the program covered ~8 million members, lifting member ARPU by ~22% year-over-year.
Collecting preference data lets Feihe tailor promotions and products, which research shows can cut churn by ~15-25% and raise customer lifetime value in China's infant-formula market.
Educational Face-to-Face Seminars
Feihe runs thousands of offline seminars and mother classes annually-about 3,500 events in 2024-delivering parenting advice and nutrition education to directly engage caregivers and build trust.
Led by certified experts and nutritionists, these high-touch sessions strengthen emotional rapport and brand positioning, driving higher conversion and repeat purchase rates in lower-tier cities where personalized advice is prized.
Digital Community and Social Media Engagement
Feihe keeps active on WeChat, Douyin and Little Red Book to reach tech – savvy parents, posting educational videos, user content and interactive campaigns; its Douyin channel reported 1.2 million followers and 15m views in 2024, boosting brand recall.
Specialized One-on-One Customer Support
Feihe offers specialized one-on-one support via hotlines and digital chat, resolving inquiries and nutrition questions fast and reinforcing its premium positioning; in 2024 Feihe reported a 15% higher retention among users who contacted support within 30 days.
Knowledgeable staff handle complex infant-health questions, building trust and boosting lifetime value; customer-service-led NPS rose to 62 in 2024, supporting higher ASPs and repeat purchase rates.
- Dedicated hotlines + chat
- 15% higher retention after contact
- NPS 62 in 2024
- Supports premium pricing and LTV
Brand Trust and National Pride Connection
Feihe ties customer relationships to national pride, framing itself as the protector of Chinese babies and leveraging roots in Heilongjiang to build trust; in 2024 Feihe reported RMB 16.9 billion revenue, up 18% y/y, showing consumer loyalty vs multinationals.
- Emotional bond: domestic trust fuels repeat purchases
- Marketing: local culture, provenance claims
- Market impact: ~20% market share in premium infant formula (2024)
Feihe: Omni – channel growth fuels RMB16.9B revenue, 8M members & ~20% premium share
Feihe's omni-channel relationships (Xing Ma Hui: ~8M members, +22% ARPU 2024), 3,500 offline classes, Douyin 1.2M followers/15M views, hotline/chat driving +15% retention and NPS 62, support ~20% premium market share and RMB16.9B revenue (+18% y/y 2024).
| Metric | 2024 |
|---|---|
| Members | 8M |
| ARPU growth | +22% |
| Events | 3,500 |
| Douyin | 1.2M/15M |
| Retention lift | +15% |
| NPS | 62 |
| Revenue | RMB16.9B (+18%) |
| Market share | ~20% |
Channels
Specialty Mother-and-Baby Stores
Specialty mother-and-baby stores are Feihe's primary channel, driving roughly 45-55% of retail sales in 2024 and delivering higher repeat purchase rates thanks to strong consumer trust. These stores give parents expert advice and tactile product trials, and Feihe secures prominent shelf space and exclusive promotions-especially critical for penetrating Tier 3-4 cities where these outlets account for ~60% of local infant formula distribution.
Major E-commerce and Marketplace Platforms
Feihe runs flagship stores on Tmall, JD.com and others, driving urban home-delivery sales-online channels accounted for ~58% of group revenue in 2024 (Feihe Dairy annual report, 2024).
These stores enable targeted ads, Singles Day promos (Nov 11) and product A/B tests while syncing with offline retail for unified inventory, loyalty and consumer-data capture.
Modern Retail, Supermarkets, and Hypermarkets
Strategic placement in chains like Walmart and Carrefour makes Feihe available during routine grocery trips, boosting reach-modern trade accounted for about 42% of China's infant formula retail sales in 2024, helping Feihe hit national penetration targets. Supermarkets offer high visibility, seasonal promotions, and large-scale displays to attract broad, convenience-seeking demographics, complementing specialized mother-and-baby stores.
Direct-to-Consumer (DTC) Mobile Apps
Feihe's DTC mobile apps and WeChat mini-programs let customers buy directly, cutting distributors and lifting gross margins (Feihe reported 2024 direct-sales growth of ~28% and DTC mix ~22% of revenue in H1 2024).
Apps tie into Feihe's loyalty program for repeat purchase - increasing ARPU and retention - and create a data-rich channel critical for long-term brand advocacy.
- Direct-sales mix ~22% of revenue (H1 2024)
- Direct-sales growth ~28% (2024 vs 2023)
- DTC improves gross margin and customer data
Interactive Offline Promotional Events
Feihe runs roadshows, mall product launches, and community events to boost trial and brand recall, converting local foot traffic into sales; in 2024 Feihe reported that in-store demos and events contributed roughly 12% of retail volume in pilot cities like Shanghai and Chengdu.
These events showcase product features, hand out samples, and engage families in a fun setting-average sample-to-purchase conversion was ~4.5% in 2024, with event-driven SKU lift of 8-15% during promotion weeks.
- Hosts roadshows, mall launches, community events
- 2024: events drove ~12% retail volume in pilot cities
- Sample-to-purchase conversion ~4.5% (2024)
- Event-driven SKU lift 8-15% during promo weeks
- Focus: engage families, demonstrate features, convert awareness to sales
Feihe omnichannel surge: marketplaces 58%, DTC +28%, strong specialty & modern trade
Feihe uses specialty mother-and-baby stores (45-55% retail sales, ~60% in Tier 3-4), online marketplaces (58% group revenue 2024), modern trade (~42% of China infant formula retail 2024), DTC/apps (22% revenue H1 2024, +28% y/y), and events (12% pilot-city volume 2024; 4.5% sample-to-purchase).
| Channel | Key metric (2024) |
|---|---|
| Specialty stores | 45-55% sales; ~60% Tier3-4 |
| Online marketplaces | 58% group revenue |
| Modern trade | ~42% retail market share |
| DTC/apps | 22% revenue; +28% growth |
| Events | 12% pilot volume; 4.5% conv. |
Customer Segments
High-End Urban Parents
High-End Urban Parents are affluent families in Tier 1-2 Chinese cities who pay 20-40% above market prices for Feihe's AstroBaby and super-premium lines, prioritizing scientific innovation and verified functional claims like immunity gains or neurodevelopmental nutrients; about 18% of urban newborn households fit this profile as of 2024. Reaching them needs targeted digital campaigns and KOLs that emphasize Feihe's R&D investment (Feihe reported RMB 210m R&D spend in 2024) and adherence to international standards (ISO 22000, GMP).
Health-Conscious Middle-Class Families
The expanding Chinese middle class-estimated at 430 million adults in 2024-prioritizes quality and value, shifting toward premium infant formula as disposable income rose ~6% in 2023; these health-conscious families drive Feihe's premium volume growth, contributing an estimated 35-45% of recent sales in higher-tier SKUs.
Consumers in Expanding Lower-Tier Cities
As wealth spreads into Tier 3-4 and rural China, these consumers form a massive growth pool-rural disposable income rose 6.2% in 2024, and provincial surveys show formula penetration up 8-12% versus 2019. Parents are shifting from unbranded milk to specialty infant formula, guided by local mother – and – baby shop owners who account for ~40% of Feihe's retail influence in lower – tier cities. Feihe's 2025 distribution footprint of 200,000+ outlets targets rapid share gains by leveraging domestic positioning as "more suitable" for local needs.
Aging Population Seeking Adult Nutrition
Feihe targets China's 260+ million adults aged 60+ (2023 census estimate) with adult milk powders formulated for bone health and immune support, turning aging demographics into a diversification play as birth rates fell to 7.52 births/1,000 in 2023.
These consumers favor trusted brands; Feihe markets longevity, vitality, and its 1962 scientific heritage to capture premium margins and repeat purchases.
- Addressable market: ~260M seniors (2023)
- Strategy: bone + immune formulations
- Value prop: brand trust, scientific heritage (since 1962)
- Demographic tailwind: low birth rate supports diversification
- Revenue upside: higher ARPU from premium adult formulas
Expectant Mothers and New Parents
Expectant mothers and new parents are Feihe's gateway customers; Feihe offers prenatal supplements and educational content to build trust during pregnancy so the brand is top-of-mind at formula transition-capturing them early raises lifetime value (Feihe reported 2024 domestic infant formula revenue of RMB 14.2bn, showing strong retention potential).
These customers need high emotional support and clear, evidence-based guidance; targeting them reduces switch risk at first feeding and increases repeat purchases and premium product uptake.
- Entry point: pregnancy research to first purchase
- Tools: prenatal supplements + educational content
- Goal: be first choice at formula transition
- Needs: emotional support, reliable info
- 2024 signal: RMB 14.2bn infant formula revenue
Feihe targets premium parents, 430M middle – class buyers, rural reach & elder market growth
Feihe's customers: affluent Tier 1-2 parents (18% of urban newborn households, pay 20-40% premium), expanding middle class (430M adults, 35-45% premium SKU sales), Tier 3-4 rural buyers (200k+ outlets, formula penetration +8-12% vs 2019), seniors (~260M, 2023) and expectant mothers (2024 infant formula revenue RMB 14.2bn).
| Segment | Key stat | 2024 signal |
|---|---|---|
| High – end parents | 18% newborn HH | RMB 210m R&D |
| Middle class | 430M adults | 35-45% premium sales |
| Lower tiers | +8-12% penetration | 200k+ outlets |
| Seniors | ~260M (2023) | Diversification focus |
| Expectant mothers | Gateway cohort | RMB 14.2bn infant revenue |
Cost Structure
Raw Material and Procurement Costs
A major share of Feihe's cost structure is raw milk and specialty inputs (OPO, lactoferrin); in 2024 procurement accounted for an estimated 40-50% of COGS, reflecting premiums paid for certified supply chains to safeguard purity and nutrients. Global dairy commodity swings-milk powder up ~18% in 2023-24-raise costs for imported ingredients, making this the largest variable cost tightly linked to Feihe's quality promise.
Marketing and Advertising Expenditures
Feihe spends heavily on brand building to defend its No.1 domestic infant formula spot, with 2024 marketing spend estimated at ~RMB 3.6 billion (≈USD 520M), covering TV, digital ads, celebrity endorsements, and large offline events.
Research and Development Investment
Feihe spends heavily on R&D to keep its 'more suitable' positioning: in 2024 R&D and technical service costs rose to CNY 1.2 billion (≈$165M), covering advanced labs, clinical trials, and ~350 scientists and nutritionists.
Manufacturing and Facility Operations
Feihe's vertically integrated plants drive high capex and opex: in 2024 Feihe spent roughly CNY 2.1 billion on production capex and CNY 850 million on facility O&M, driven by energy, labor, equipment upgrades, and regulatory compliance.
The fresh-model adds continuous monitoring and higher throughput needs, raising per – ton processing costs by an estimated 8-12% versus conventional lines, but preserves brand quality and safety.
- 2024 capex ~ CNY 2.1B
- 2024 facility O&M ~ CNY 850M
- Freshness premium +8-12% per – ton cost
- Main costs: energy, labor, upgrades, compliance
Logistics and Distribution Management
Moving formula nationwide drives high warehousing, transport and cold-chain costs; Feihe reported logistics and distribution expenses near 7% of revenue in 2024 (≈RMB 1.1bn on RMB 15.7bn sales), reflecting refrigerated storage and last-mile delivery to remote provinces.
Maintaining product integrity and a large distributor network adds sales-support and inventory carrying costs; efficient logistics directly protects margins and reduces stockouts.
- ~7% revenue on logistics (2024)
- RMB 1.1bn logistics spend (2024)
- Cold-chain critical for remote last-mile
- Distributor support raises operating costs
Feihe 2024: Raw milk drives 40-50% COGS; marketing Rmb3.6bn, capex Rmb2.1bn
Feihe's 2024 costs concentrated in raw milk & specialty inputs (40-50% COGS), marketing ~RMB 3.6bn, R&D CNY 1.2bn, capex CNY 2.1bn, facility O&M CNY 850m, logistics ~7% revenue (RMB 1.1bn); fresh-model raises per – ton processing costs +8-12%.
| Item | 2024 |
|---|---|
| Procurement | 40-50% COGS |
| Marketing | RMB 3.6bn |
| R&D | RMB 1.2bn |
| Capex | RMB 2.1bn |
| O&M | RMB 850m |
| Logistics | RMB 1.1bn (7%) |
Revenue Streams
Super-Premium Infant Formula Sales
Feihe's super-premium lines, led by AstroBaby, are the top revenue drivers and deliver the highest gross margins-about 28-32% in 2024 versus 18-22% for mass brands-fuelling roughly 55% of group sales in 2024 (RMB basis).
These SKUs target affluent, low-price-sensitivity buyers who pay for clinical positioning and perceived quality; R&D claims and premium pricing sustain unit economics and corporate profitability while reinforcing Feihe's market-leader image.
Premium and Regular Formula Products
Feihe sells mid-tier and regular infant formula to capture price-sensitive buyers, driving volume: in FY2024 these segments made up about 38% of unit sales and roughly 22% of revenue, supporting scale despite lower gross margins than super-premium lines. They're critical in lower-tier cities and rural China, where price competition is fierce, and act as a gateway product that converts first-time buyers into Feihe's higher-margin ecosystem over subsequent purchases.
Adult Milk Powder and Nutrition Revenue
Sales of specialized adult and elderly milk powders at Feihe (Feihe International, 6186.HK) are a fast-growing revenue stream, with adult-nutrition sales rising ~28% year-on-year in 2024 and accounting for an estimated 12-15% of group revenue by FY2024. These products diversify risk from falling birth rates in China (2023 births 9.56M, a 2.8% drop) and use Feihe's brand and 80,000+ retail outlets and e-commerce channels to expand margins and customer reach.
Nutritional Supplements and Specialty Dairy
Feihe also earns from high-margin dietary supplements-vitamins and probiotics-targeted at pregnant women and children, boosting gross margins above core infant formula (Feihe reported 2024 gross margin ~43.5% on formula; supplements typically add 5-8ppt).
The firm sells liquid milk and dairy snacks in select regions, driving incremental revenue and raising household nutrition share; cross-selling lifts same-customer ARPU by ~12% in 2023 pilots.
- Supplements: targeted, high margin (+5-8ppt)
- Cross-sell: raises ARPU ~12%
- Dairy snacks/liquid milk: regional growth lever
- Captures larger family nutrition budget
Other Dairy Product Sales and Services
AstroBaby fuels 55% of Feihe sales with higher margins; adult nutrition surges +28% YoY
Feihe's super – premium infant formula (AstroBaby) drove ~55% of 2024 group sales with 28-32% gross margins; mid/regular tiers were ~22% revenue (38% unit share) with 18-22% margins; adult/elderly nutrition grew ~28% YoY in 2024, contributing ~12-15% of revenue; supplements added ~5-8ppt to margins; non – core B2B/raw milk ~3-5% of 2024 revenue.
| Stream | 2024 % Rev | Gross Margin | Notes |
|---|---|---|---|
| Super – premium | ~55% | 28-32% | AstroBaby lead |
| Mid/regular | ~22% | 18-22% | 38% unit share |
| Adult/elderly | 12-15% | ~30% est. | +28% YoY |
| Supplements | - | +5-8ppt vs formula | Target: pregnant/children |
| B2B/raw milk | 3-5% | Lower | Surplus monetization |
Frequently Asked Questions
It gives a clear, boardroom-ready snapshot of Feihe across the 9 Business Model Canvas blocks. That means you can quickly see how it creates, delivers, and captures value without building the framework from scratch, which helps with faster commercial due diligence and sharper strategic review.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.